The 6 analysts offering 12-month price forecasts for Clovis Oncology Inc have a median target of 6.00, with a high estimate of 23.00 and a low estimate of 4.00. The median estimate represents a -13.92% decrease from the last price of 6.97.
The current consensus among 7 polled investment analysts is to Hold stock in Clovis Oncology Inc. This rating has held steady since September, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.00
Reporting Date Oct 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.